Video 15 Oct 2020

2020: a game changer year for AMR? (Video)

At the AMR Congress 2020, Dame Sally Davies, UK AMR Special Envoy asked Thomas Cueni, IFPMA’s Director General, if industry has done enough to tackle AMR and what remains to be done to create a sustainable market and long-term R&D investment into antibiotics.

Statement 13 Oct 2020

Biopharmaceutical industry support EU regulators exceptional transparency measures and call other regulatory authorities to follow suit to help ensure confidence in the science and the decision-making

Geneva, 13 October 2020: IFPMA & EFPIA support European Medicines Agency’s (EMA) initiative to implement exceptional transparency measures that are targeting regulatory activities for the assessment and approval of medicines and vaccines for COVID-19.[1] The biopharmaceutical industry represented by IFPMA and EFPIA encourage other national regulatory authorities to follow EMA’s example. The European Medicines Agency...

Press release 13 Oct 2020

IFPMA applauds APEC for trailblazing efforts to demonstrate return on ethics for SMEs through Vision 2025

GENEVA, 13 October 2020: Today, IFPMA joined hundreds of diverse stakeholders from more than 30 economies spanning the Asia-Pacific and beyond in a shared commitment to solidify and grow the world’s largest public-private, multi-sectoral partnership in the advancement of business ethics in the medical device and biopharmaceutical sectors, through Vision 2025. This roadmap builds on...

Expert insight 13 Oct 2020

Supporting the emergence of a new generation of industry leaders for sustainable global health

Since the beginning of the COVID-19 crisis, innovative players and industries operating in the health sector have been pressed to collaborate, innovate, and accelerate their research and development efforts in response to these unprecedented times. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the trade association that represents biopharmaceutical companies around the world, has...

Expert insight 9 Oct 2020

5 Questions… to Wendy Orchard on mental health & COVID-19

In the lead up to World Mental Health Day we sat down with Wendy Orchard, Executive Director of the International Association for Suicide Prevention (IASP) as she prepares to hold a virtual March for mental health, to find out what has been the impact of COVID-19 on mental health and what are the global efforts...

Statement 6 Oct 2020

IFPMA Statement for the Special session of the Executive Board on implementation of Resolution WHA73.1

COVID-19 is a human, social, and economic tragedy that, as of September 2020, has cost more than a million lives globally and is estimated to contract global GDP by $US 7 trillion in 2020. Since the early days of this pandemic, the R&D-based biopharmaceutical industry has responded through many initiatives aimed at providing and prioritizing...

Position paper 5 Oct 2020

Ethical third party intermediary relationships in the biopharmaceutical sector

To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (“Companies”) to contract with third parties to support their business activities. These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants,...

Video 5 Oct 2020

5 lessons as COVID-19 unfolds for future pandemics – Insights from the biopharmaceutical industry

Thomas Cueni, Director General of IFPMA, participated in the Science and Technology in Society Forum (STS Forum) on 4th October 2020, in a session titled “Improving Preparedness for Pandemic Diseases: the Role of Science and Technology”. Other speakers included PeggyHamburg (former Commissioner, US FDA, Prof. Yamanaka (Nobel Laureate 2012), and Prof. Tan from (Ministry of...

Expert insight 5 Oct 2020

5 Questions to … Eric de Roodenbeke

Hospitals have been at the forefront in fighting the COVID-19 pandemic. We sat down with Eric de Roodenbeke, CEO of the International Hospital Federation to talk about how hospitals have adapted to the new normal as we continue to grapple with the pandemic. 5 Questions to … Eric de Roodenbeke The IHF has celebrated its...

Statement 29 Sep 2020

WHO PAHO 72nd Regional Committee: COVID-19 Pandemic in the Region of the Americas

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), supported by FIFARMA and PhRMA is pleased to contribute this statement to the 72nd Session of the Regional Committee of WHO for the Americas. COVID-19 has had profound health, social and economic impacts in the Americas and worldwide, having also led to delayed diagnosis and treatment...

Expert insight 25 Sep 2020

Creating a New Generation of Antibiotics webinar – opportunity to explain how pharma has stepped to the plate

I recently participated in Chatham House Webinar: Creating a New Generation of Antibiotics. It was a great opportunity for me to tell Jim O’ Neill, how little over a year ago, he played a role in speeding up industry action on AMR – something I had decided the IFPMA should engage on when I took...

Statement 22 Sep 2020

Innovative health industries united in welcoming UNGA Resolution on “Comprehensive and Coordinated Response to the COVID-19 Pandemic”

Innovative health industries united in welcoming United Nations General Assembly Resolution on ‘Comprehensive and Coordinated Response to the COVID-19 Pandemic’ On behalf of global biopharmaceutical and medical technologies companies, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the International Council of Biotechnology Associations (ICBA), the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade...